2020 AliquantumRx receives TEDCO funding

 AliquantumRx Inc. announces a phase III MII funding for a project entitled “Development of Cethromycin salt (QB101) for the treatment of dormant malaria”. Created by the General Assembly and administered by TEDCO, the MII promotes the commercialization of research conducted in five qualifying Maryland universities. The initiative encourages universities to partner on commercialization proposals, strategies […]